Dolutegravir/rilpivirine (Juluca®)is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||08/06/2018|
|Rapid review completed||12/07/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Juluca® not be considered for reimbursement at the submitted price in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations – October 2018.